Claims
- 1. A method for treating cerebral ischemia in a mammal, comprising the step of administering to the mammal an amount of a compound selected from those of formula (I): ##STR28## in which: R.sub.1, R.sub.2, and R.sub.3, which are identical or different, represent hydrogen, halogen, linear or branched (C.sub.1 -C.sub.6) alkyl which is unsubstituted or substituted with one or a number of halogen atoms or nitro, cyano, or aminosulfonyl groups,
- or alternatively, when two of R.sub.1, R.sub.2, and R.sub.3, are located on adjacent carbons, form, with the carbon atoms to which they are attached, a (C.sub.3 -C.sub.7) cycloalkene ring or a benzene ring which is unsubstituted or substituted with one or a number of halogen atoms or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, or trihalomethyl groups,
- R.sub.4 represents hydrogen, linear or branched (C.sub.1 -C.sub.6) alkyl, phenyl which is unsubstituted or substituted with one or a number of halogen atoms or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, or trihalomethyl, or a group ##STR29## in which R.sub.6 and R.sub.7, which are identical or different, represent a hydrogen atom or linear or branched (C.sub.1 -C.sub.6) alkyl, which is unsubstituted or substituted with (C.sub.3 -C.sub.7) cycloalkyl or with phenyl,
- R.sub.5 represents hydrogen, hydroxyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, phenoxy, mercapto, linear or branched (C.sub.1 -C.sub.6) alkylthio, linear or branched (C.sub.1 -C.sub.6) alkyl which is unsubstituted or substituted with (C.sub.3 -C.sub.7) cycloalkyl, phenyl which is unsubstituted or substituted with one or a number of halogen atoms or with linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, or trihalomethyl, or amino which is unsubstituted or substituted with one or two linear or branched (C.sub.1 -C.sub.6) alkyl, or a group ##STR30## in which R.sub.6 and R.sub.7 are as defined above, its isomers, and its addition salts with a pharmaceutically-acceptable acid or base, which is effective for alleviation of said condition.
- 2. The method of claim 1 wherein at least one of the groups R.sub.1, R.sub.2, and R.sub.3 represents chlorine.
- 3. The method of claim 1 wherein R.sub.4 represents hydrogen.
- 4. The method of claim 1 wherein R.sub.5 represents hydroxyl.
- 5. The method of claim 1 wherein the compound is 6,7-dichloro-2(1H)-quinolone-3-phosphonic acid.
- 6. The method of claim 1, wherein an effective amount of the compound is administered in admixture with one or more pharmaceutically-acceptable excipients or vehicles.
- 7. The method of claim 1 wherein the compound is 6-chloro-7,8,9,10-tetrahydro-2(1H)-benzo[h]quinolone-3-phosphonic acid.
- 8. The method of claim 6 wherein the compound is 6-nitro-7,8,9,10-tetrahydro-2(1H)-benzo[h]quinolone-3-phosphonic acid.
- 9. The method of claim 1 wherein the compound is monoethyl ester of 6-nitro-7,8,9,10-tetrahydro-2(1H)-benzo[h]quinolone-3-phosphonic acid.
Priority Claims (1)
Number |
Date |
Country |
Kind |
93 10379 |
Aug 1993 |
FRX |
|
Parent Case Info
The present application is a division of our prior-filed application Ser. No. 08/297,793, filed Aug. 30, 1994, now U.S. Pat. No. 5,536,709.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4124558 |
Hardtmann et al. |
Nov 1978 |
|
4898854 |
Hutchison et al. |
Feb 1990 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
297793 |
Aug 1994 |
|